纳武利尤单抗对比索拉非尼治疗晚期肝细胞癌(CheckMate 459):一项随机、多中心、开放标签、3期试验
这项在22个国家和地区开展的随机、开放标签、3期试验纳入743例不可手术或局部治疗后进展、未接受过系统治疗的晚期肝细胞癌患者,按1:1随机接受纳武利尤单抗(240 mg 静脉注射,每2周一次)或索拉非尼(400 mg 口服,每日两次)。纳武利尤单抗组中位总生存期16.4个月(95%CI 13.9-18.4),索拉非尼组14.7个月(95%CI 11.9-17.2),HR 0.85(95%CI 0.72-1.02),p=0.075,未达到预设的显著性水平p=0.0419,两组总生存期无显著差异。
要点
- 纳武利尤单抗组中位总生存期16.4个月,索拉非尼组14.7个月,HR 0.85(95%CI 0.72-1.02),p=0.075,未达预设显著性水平p=0.0419。
- 纳武利尤单抗组最常见的≥3级治疗相关不良事件为天冬氨酸氨基转移酶升高(6%),索拉非尼组为掌跖红斑感觉异常(14%)和高血压(7%)。
- 作者认为,对于酪氨酸激酶抑制剂和抗血管生成药物有禁忌或存在显著风险的患者,纳武利尤单抗可考虑作为一种治疗选择。
核心结论
- 一线纳武利尤单抗治疗对比索拉非尼未显著改善晚期肝细胞癌患者的总生存期,但观察到临床活性和有利的安全性特征。
- 作者认为,对于酪氨酸激酶抑制剂和抗血管生成药物有禁忌或存在显著风险的患者,纳武利尤单抗可考虑作为一种治疗选择。
研究设计与样本
- 随机、开放标签、3期试验,在亚洲、大洋洲、欧洲和北美22个国家和地区的医疗中心开展。
- 纳入至少18岁、组织学确诊的晚期肝细胞癌、不适合或手术后或局部区域治疗后进展、既往未接受肝细胞癌系统治疗、Child-Pugh A级、ECOG体能状态评分0或1、不论病毒性肝炎状态的患者。
- 通过交互式语音应答系统按1:1随机分配接受纳武利尤单抗(240 mg 静脉注射,每2周一次)或索拉非尼(400 mg 口服,每日两次),直至疾病进展或不可接受的毒性。
- 主要终点为意向治疗人群的总生存期;安全性在所有至少接受一剂研究药物的患者中评估。
- 2016年1月11日至2017年5月24日共随机分配743例患者(纳武利尤单抗组 n=371,索拉非尼组 n=372)。
主要发现
- 主要分析时,纳武利尤单抗组中位总生存期随访15.2个月(IQR 5.7-28.0),索拉非尼组13.4个月(IQR 5.7-25.9)。
- 纳武利尤单抗组中位总生存期16.4个月(95%CI 13.9-18.4),索拉非尼组14.7个月(95%CI 11.9-17.2),HR 0.85(95%CI 0.72-1.02),p=0.075,未达到方案预设的显著性水平p=0.0419,最短随访22.8个月。
- 最常见的≥3级治疗相关不良事件:掌跖红斑感觉异常在纳武利尤单抗组367例中1例(<1%),索拉非尼组52例(14%);天冬氨酸氨基转移酶升高在纳武利尤单抗组22例(6%),索拉非尼组13例(4%);高血压在纳武利尤单抗组0例,索拉非尼组26例(7%)。
- 严重治疗相关不良事件:纳武利尤单抗组43例(12%),索拉非尼组39例(11%)。
- 治疗相关死亡:纳武利尤单抗组4例,索拉非尼组1例。
关键数值与推荐
- 纳武利尤单抗组中位总生存期16.4个月(95%CI 13.9-18.4)对比索拉非尼组14.7个月(95%CI 11.9-17.2),HR 0.85(95%CI 0.72-1.02),p=0.075,未达到预设显著性水平p=0.0419。
- 纳武利尤单抗组≥3级掌跖红斑感觉异常1例(<1%,共367例)对比索拉非尼组52例(14%)。
- 纳武利尤单抗组≥3级天冬氨酸氨基转移酶升高22例(6%)对比索拉非尼组13例(4%)。
- 纳武利尤单抗组≥3级高血压0例对比索拉非尼组26例(7%)。
- 严重治疗相关不良事件:纳武利尤单抗组43例(12%)对比索拉非尼组39例(11%);治疗相关死亡:纳武利尤单抗组4例对比索拉非尼组1例。
临床怎么用
- 作者认为,对于酪氨酸激酶抑制剂和抗血管生成药物有禁忌或存在显著风险的患者,纳武利尤单抗可考虑作为一种治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1-2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients with advanced hepatocellular carcinoma. METHODS: In this randomised, open-label, phase 3 trial done at medical centres across 22 countries and territories in Asia, Australasia, Europe, and North America, patients at least 18 years old with histologically confirmed advanced hepatocellular carcinoma not eligible for, or whose disease had progressed after, surgery or locoregional treatment; with no previous systemic therapy for hepatocellular carcinoma, with Child-Pugh class A and Eastern Cooperative Oncology Group performance status score of 0 or 1, and regardless of viral hepatitis status were randomly assigned (1:1) via an interactive voice response system to receive nivolumab (240 mg intravenously every 2 weeks) or sorafenib (400 mg orally twice daily) until disease progression or unacceptable toxicity. The primary endpoint was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study drug. This completed trial is registered with ClinicalTrials.gov, NCT02576509. FINDINGS: Between Jan 11, 2016, and May 24, 2017, 743 patients were randomly assigned to treatment (nivolumab, n=371; sorafenib, n=372). At the primary analysis, the median follow-up for overall survival was 15·2 months (IQR 5·7-28·0) for the nivolumab group and 13·4 months (5·7-25·9) in the sorafenib group. Median overall survival was 16·4 months (95% CI 13·9-18·4) with nivolumab and 14·7 months (11·9-17·2) with sorafenib (hazard ratio 0·85 [95% CI 0·72-1·02]; p=0·075; minimum follow-up 22·8 months); the protocol-defined significance level of p=0·0419 was not reached. The most common grade 3 or worse treatment-related adverse events were palmar-plantar erythrodysaesthesia (1 [<1%] of 367 patients in the nivolumab group vs 52 [14%] of patients in the sorafenib group), aspartate aminotransferase increase (22 [6%] vs 13 [4%]), and hypertension (0 vs 26 [7%]). Serious treatment-related adverse events were reported in 43 (12%) patients receiving nivolumab and 39 (11%) patients receiving sorafenib. Four deaths in the nivolumab group and one death in the sorafenib group were assessed as treatment related. INTERPRETATION: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib, but clinical activity and a favourable safety profile were observed in patients with advanced hepatocellular carcinoma. Thus, nivolumab might be considered a therapeutic option for patients in whom tyrosine kinase inhibitors and antiangiogenic drugs are contraindicated or have substantial risks. FUNDING: Bristol Myers Squibb in collaboration with Ono Pharmaceutical.
引用
- Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2021. PMID: 34914889. doi:10.1016/S1470-2045(21)00604-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。